Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MANAGE: Dabigatran and Omeprazole for MINS
NCT01661101Phase 3Completed
- Sponsor
- Population Health Research Institute
- Start
- Jan 2013
- Primary completion
- Mar 2018
- Modality
- Small Molecules
- Countries
- 19
01
Overview
Phase 3, randomised, double-blind trial of dabigatran etexilate oral solution and omeprazole in Myocardial injury (4 arms), sponsored by Population Health Research Institute. Primary endpoints: Major vascular complication (for Dabigatran) at 1 year and Major upper gastrointestinal complication (for Omeprazole) at 1 year. Started Jan 2013; status: completed.
02
Drugs
dabigatran etexilate oral solutionomeprazole
03
Conditions
Myocardial injury
Beyond the preview
Go deeper on NCT01661101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01661101.